Compositions, methods, and systems for the synthesis and use of imaging agents
US-9713651-B2 · Jul 25, 2017 · US
Contrast agents for myocardial perfusion imaging
US10125106B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10125106-B2 |
| Application number | US-201715629068-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 21, 2017 |
| Priority date | Feb 13, 2004 |
| Publication date | Nov 13, 2018 |
| Grant date | Nov 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having the structure: 2. A composition, comprising: the compound of claim 1 and a solvent. 3. A compound having the structure: 4. A composition comprising: the compound of claim 3 and a solvent. 5. A precursor compound to a 18 F labeled contrast agent of formula: wherein the precursor compound has the formula: and L G is a leaving group that can be replaced in an S N 2 displacement reaction to produce the 18 F labeled contrast agent. 6. The precursor compound of claim 5 , wherein the precursor compound is provided in a solution. 7. The precursor compound of claim 5 , wherein the precursor compound is provided as a solid preparation. 8. The precursor compound of claim 7 , wherein the solid preparation is a lyophilized solid.
Assignees
Inventors
Classifications
Echographic preparations; Ultrasonic imaging preparations · CPC title
Small organic molecules (oligomers, polymers, dendrimers A61K49/0054) · CPC title
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine · CPC title
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title
- A61K49/10Primary
Organic compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10125106B2 cover?
- The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
- Who is the assignee on this patent?
- Lantheus Medical Imaging Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K49/10. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).